Rock Springs Capital

Develops immunotherapies that selectively deplete cytotoxic T cells to treat autoimmune diseases

Develops next-generation RNAi therapeutics and engineering platform for multiple disease areas

Develops medicines targeting historically undruggable protein targets in cancer